1. Ramucirumab-related Oral Pyogenic Granuloma: A Report of Two Cases
- Author
-
Yasuyuki Michi, Tadanobu Aragaki, Hisashi Hosaka, Tetsuya Yoda, Yasuyuki Fukai, Nobuyoshi Tomomatsu, and Misa Iijima
- Subjects
Male ,medicine.medical_specialty ,Angiogenesis ,030204 cardiovascular system & hematology ,Antibodies, Monoclonal, Humanized ,Ramucirumab ,Lesion ,03 medical and health sciences ,0302 clinical medicine ,Oral pyogenic granuloma ,Tongue ,Internal Medicine ,medicine ,Humans ,Granuloma, Pyogenic ,Aged ,Pyogenic granuloma ,business.industry ,Upper lip ,Mouth Mucosa ,Cancer ,General Medicine ,Middle Aged ,medicine.disease ,Dermatology ,Lip ,stomatognathic diseases ,medicine.anatomical_structure ,030211 gastroenterology & hepatology ,medicine.symptom ,business - Abstract
Pyogenic granuloma (PG) is a granulomatous elevated lesion that occurs on the skin and mucous membranes. We herein report two cases of intra-oral PG that developed during the administration of ramucirumab for gastric cancer. Case 1 involved a 55-year-old man with a 6-mm tumor on the right tongue, and case 2 involved a 67-year-old man with a 5-mm tumor on the upper lip. The imbalance in angiogenesis caused by ramucirumab and the deterioration in the local oral environment were suggested to have caused the PG. Medical and dental collaboration is essential during the administration of ramucirumab.
- Published
- 2021